Variant Perception

Where We Disagree With the Market

The sharpest disagreement is that Convatec's next rerating test is not whether management can repeat the headline 5-7% ex-InnovaMatrix growth guide; it is whether that growth converts into owner earnings after all growth capex and working-capital leakage. Market perception is mixed but observable: sell-side snippets are Buy-heavy and target upside is positive, while the stock trades near a 52-week low and only near its own historical EV / EBITDA average. The market appears willing to treat the Accelerate plan as credible if guidance is reiterated; our evidence says the cash-conversion denominator changed at exactly the point when capex, receivables, payables, and reimbursement risk became more important. The debate should resolve through the 21 May 2026 trading update, 4 August 2026 H1 results, and FY2026 cash-flow reconciliation.

Variant Perception Scorecard

The score is high but not extreme. Consensus is clear enough on analyst tone and the Accelerate narrative, but not a single monolithic belief because the tape is already weak and some analysts have flagged valuation and InnovaMatrix risk. Evidence strength is stronger than consensus clarity because the cash-definition gap, working-capital data, impairment, and catalyst dates are all observable rather than interpretive. The edge is not calling Convatec low quality; it is requiring proof that adjusted growth is becoming comparable cash earnings before giving the stock an acceleration multiple.

Consensus Map

The Disagreement Ledger

Consensus would say cash generation has already been proven: FY2025 operating cash flow was $470m, new-definition FCFE was $362m, and the company returned substantial cash while keeping adjusted leverage around 2.0x. The contrary evidence is that the comparable FCFE number was only $219m, prior-definition conversion was 61%, receivables grew far faster than revenue, and payables supplied cash against customer and inventory outflows. If this view is right, the market would have to concede that the correct multiple should be applied to a lower and less settled owner-earnings base. The cleanest disconfirming signal is FY2026 old-definition conversion moving above 90% with receivables and payables normalizing.

Consensus would say InnovaMatrix is visible, reflected, and small: the market has already seen the CMS rate reset, and management has separated the base business with ex-InnovaMatrix guidance. The evidence disagrees because InnovaMatrix moved from growth proof point to impairment in a short period, and the 2027 acceleration plan still depends on evidence generation, market access, product launches, and reimbursement execution. If this view is right, the market would have to concede that a small product can still change the required trust discount for the wider pipeline. The cleanest disconfirming signal is FY2026 InnovaMatrix revenue holding near the reset guide with no further impairment and no similar reimbursement surprise elsewhere.

Consensus would say the FDA letter is not thesis-breaking because it did not allege product-safety issues or restrict production, marketing, manufacturing, or distribution. The evidence disagrees only modestly but importantly: Infusion Care was the fastest-growing category in FY2025, and quality remediation sits inside the growth engine rather than a peripheral business. If this view is right, the market would have to concede that the growth mix is more operationally fragile than the headline category growth suggests. The cleanest disconfirming signal is visible FDA progress with continued double-digit Infusion growth and no OEM customer disruption.

Evidence That Changes the Odds

How This Gets Resolved

What Would Make Us Wrong

The cash-denominator disagreement breaks first if FY2026 shows old-definition equity cash conversion above 90%, all-capex free cash flow still strong, receivables growing at or below revenue, and payables no longer doing heavy lifting in the working-capital bridge. That would mean FY2025 was a transition year in presentation and collection timing, not a structural step-down in owner earnings. It would also make the $300m buyback and dividend growth look like capital allocation backed by durable cash rather than by a flattering cash metric.

The reimbursement disagreement breaks if InnovaMatrix holds near the roughly $20m reset guide, publishes or discloses evidence that supports ongoing coverage, and avoids further impairment while the rest of Advanced Wound Care keeps growing. If no similar reimbursement issue appears in ostomy, continence, or wound launches, the correct read would be that the market was right to isolate the product-specific shock. In that case the trust discount should narrow, because the base chronic-care engine already has real growth and margin evidence.

The Infusion quality concern breaks if the FDA process closes or shows clear progress with no product restrictions, no OEM customer disruption, and continued double-digit category momentum. It would break further if reported and adjusted earnings converge after the acquired-intangible amortization roll-off rather than being replaced by fresh adjustments. Those two outcomes would leave the market with a cleaner version of the bull case: defensible chronic-care growth, improving margin, and cash conversion that is again comparable across periods.

The first thing to watch is… the 21 May 2026 trading update, specifically whether management reiterates FY2026 guidance with a credible H2 bridge and no new caveats on cash conversion, receivables, InnovaMatrix, or FDA remediation.